The committee concluded from the evidence presented that XprESS is a clinically non‑inferior, but less invasive, alternative to functional endoscopic sinus surgery (FESS) in patients with uncomplicated chronic sinusitis. Compared with FESS, it may lead to faster recovery times and carries a lower risk of some complications.
The committee concluded that cost savings are plausible, but depend on the device cost of XprESS, how long a FESS procedure takes and the proportion of XprESS procedures that can be done in an outpatient setting using local anaesthetic. For example, XprESS may save £152 per patient if 80% of XprESS treatments are done in an outpatient setting using local anaesthetic, FESS takes 60 minutes and the XprESS device costs £820.
The committee considered that XprESS has the potential to treat uncomplicated chronic sinusitis earlier in disease progression than is currently available in the NHS. As such, it may improve quality of life and clinical outcomes, as well as reduce surgical waiting lists.